Primary mitochondrial disease
Khondrion B.V. is focused on mitochondrial medicine, with research centred on primary mitochondrial disease and the clinical burden associated with the m.3243A>G mitochondrial DNA variant.
- Mitochondrial DNA 3243A>G-related disease
- MIDD and MELAS
- Multi-system mitochondrial phenotypes
The sponsor’s clinical activity is directed toward conditions marked by energy metabolism impairment and broad multi-organ involvement.
Neuromuscular and functional impairment
Its research landscape includes symptoms and complications affecting skeletal muscle function, physical fatigue, and day-to-day mobility in people with mitochondrial disorders.
- Lower limb muscle weakness
- Dynamic balance control
- Physical fatigue and activity limitation
These areas reflect interest in functional outcomes that influence independence and quality of life.
Quality of life and symptom burden
Khondrion B.V. also places emphasis on patient-facing outcomes associated with chronic mitochondrial disorders, including the impact of symptoms on daily living and health-related quality of life.
- Fatigue-related disability
- Mobility and functional capacity
- Patient-reported symptom impact
Its clinical interest extends to measuring how mitochondrial disease affects practical functioning in everyday settings.
Therapeutic development in mitochondrial disorders
The company’s research activity is aligned with pharmaceutical development for inherited mitochondrial conditions, with a therapeutic focus on clinical manifestations that are difficult to manage in routine care.
- Mitochondrial dysfunction
- Multisystem disease manifestations
- Symptom-directed mitochondrial therapy
This includes attention to disorders involving both neurological and muscular involvement.
